UNSPSC 51111610: Methotrexate

This classification denotes a folate antagonist and dihydrofolate reductase inhibitor with the molecular formula C20H22N8O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YL5FZ2Y5U1, chemically known as poly(imino((1s)-1-carboxy-4-oxo-1,4-butanediyl)), alpha-(4-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)-omega-hydroxy- but generally known as methotrexate, which bears US NIH Compound Identifier 4112.

UNSPSC 51111610 Methotrexate is a Commodity code covering the procurement of methotrexate, a disease-modifying antirheumatic drug and antimetabolite used in the treatment of rheumatoid arthritis, certain malignancies, and autoimmune conditions. State and local health agencies, including state departments of health, county health departments, and state Medicaid programs, purchase methotrexate as part of formulary procurement, inpatient and outpatient pharmacy operations, and disease management programs. The drug is typically procured through standing contracts, blanket purchase orders, or cooperative purchasing arrangements that establish unit pricing and delivery terms across fiscal periods rather than through project-specific requests. Issuing bodies range from individual state health departments managing centralized pharmacy procurement to county facilities and local health systems seeking to standardize costs and ensure reliable supply.

The source provided contains no recent state and local contract opportunities tagged to this code, making it impossible to characterize current geographic concentration, issuing-body activity, or representative solicitations at this time. The absence of recent postings may indicate that methotrexate procurement is managed through standing agreements, cooperative purchasing vehicles, or non-competitive acquisition rather than through advertised RFP or IFB notices, or that recent activity has been classified under related pharmaceutical commodity codes instead.